Stock listing

OTC:CERO CERo Therapeutics Holdings, Inc. Stock

Follow CERo Therapeutics Holdings, Inc. into a list and get an email when it puts out news.

Share price · OTC:CERO

$0.0037 USD -0.0003 (-7.5%)

Close on Nov 20, 2026

Past year -94.7% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.0037 – $0.0043 USDNov 20, 2026
Volume
124,170 sharesNov 20, 2026
Market cap
$265,035 USDAt the close on Nov 20, 2026 · price × 71.63M shares outstanding
52-week range
$0.0030 – $0.1350 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$5,041 USDMedian day 299,600 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
CERo Therapeutics Holdings, Inc. logo

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OTC:CERO · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.0037-0.0003-7.5%$0.0043$0.0043$0.0037124,170
$0.0040-0.0001-2.4%$0.0041$0.0041$0.004070,020
$0.00410.00000.0%$0.0040$0.0047$0.004082,491
$0.00410.00000.0%$0.0048$0.0049$0.004134,588
$0.0041+0.0001+2.5%$0.0039$0.0048$0.0037329,551
$0.0040-0.0010-20.0%$0.0040$0.0050$0.0040179,700
$0.0050+0.0010+25.0%$0.0040$0.0050$0.004090,200
$0.0040+0.0010+33.3%$0.0050$0.0050$0.004099,300
$0.00300.00000.0%$0.0030$0.0050$0.0030123,900
$0.0030-0.0010-25.0%$0.0050$0.0050$0.0030163,700
$0.0040-0.0010-20.0%$0.0050$0.0050$0.004044,400
$0.0050+0.0010+25.0%$0.0040$0.0050$0.0040605,700
$0.00400.00000.0%$0.0040$0.0040$0.0030126,400
$0.0040-0.0010-20.0%$0.0050$0.0050$0.00301,306,900
$0.00500.00000.0%$0.0050$0.0050$0.0040211,600
$0.00500.00000.0%$0.0050$0.0050$0.0050297,300
$0.0050-0.0010-16.7%$0.0060$0.0060$0.00401,633,400
$0.0060+0.0010+20.0%$0.0050$0.0060$0.0050465,800
$0.00500.00000.0%$0.0060$0.0060$0.0040103,100
$0.00500.00000.0%$0.0050$0.0060$0.0050188,900
$0.00500.00000.0%$0.0050$0.0050$0.004042,500
$0.0050-0.0010-16.7%$0.0050$0.0060$0.0040654,100
$0.00600.00000.0%$0.0060$0.0060$0.0050234,800
$0.00600.00000.0%$0.0060$0.0070$0.0050534,700
$0.0060-0.0010-14.3%$0.0070$0.0070$0.006038,800
$0.00700.00000.0%$0.0070$0.0070$0.00501,355,800
$0.00700.00000.0%$0.0080$0.0080$0.00601,548,100
$0.0070-0.0020-22.2%$0.0090$0.0090$0.00702,056,100
$0.00900.00000.0%$0.0090$0.0090$0.00801,112,600
$0.0090-0.0010-10.0%$0.0090$0.0100$0.00901,602,900
$0.0100+0.0010+11.1%$0.0120$0.0120$0.0090858,000
$0.0090-0.0010-10.0%$0.0110$0.0110$0.0090571,200
$0.0100-0.0010-9.1%$0.0110$0.0110$0.00901,143,700
$0.01100.00000.0%$0.0110$0.0110$0.0110252,600
$0.01100.00000.0%$0.0110$0.0110$0.0110171,300
$0.01100.00000.0%$0.0110$0.0110$0.0110674,800
$0.01100.00000.0%$0.0120$0.0120$0.0110249,200
$0.01100.00000.0%$0.0110$0.0120$0.0110396,800
$0.0110-0.0010-8.3%$0.0120$0.0120$0.0100224,700
$0.01200.00000.0%$0.0120$0.0120$0.0110220,300
$0.01200.00000.0%$0.0120$0.0120$0.0100422,400
$0.0120+0.0010+9.1%$0.0100$0.0130$0.0100541,700
$0.0110+0.0010+10.0%$0.0130$0.0130$0.0100408,700
$0.0100-0.0010-9.1%$0.0090$0.0120$0.0090153,600
$0.0110-0.0020-15.4%$0.0130$0.0130$0.010071,100
$0.0130+0.0010+8.3%$0.0130$0.0130$0.0100301,900
$0.0120-0.0010-7.7%$0.0130$0.0130$0.0100223,700
$0.0130+0.0030+30.0%$0.0100$0.0130$0.0100272,800
$0.01000.00000.0%$0.0100$0.0110$0.0100401,200
$0.0100-0.0010-9.1%$0.0120$0.0120$0.0100474,400
$0.0110-0.0010-8.3%$0.0120$0.0130$0.0100483,000
$0.0120+0.0010+9.1%$0.0100$0.0130$0.01001,059,900
$0.01100.00000.0%$0.0080$0.0120$0.00801,060,300
$0.0110-0.0050-31.3%$0.0130$0.0160$0.01001,712,300
$0.0160+0.0040+33.3%$0.0120$0.0160$0.01201,807,100
$0.0120-0.0010-7.7%$0.0130$0.0140$0.0120699,700
$0.0130+0.0020+18.2%$0.0110$0.0130$0.01002,324,600
$0.0110+0.0010+10.0%$0.0100$0.0110$0.009028,500
$0.0100+0.0010+11.1%$0.0080$0.0100$0.0080262,200
$0.0090+0.0010+12.5%$0.0100$0.0100$0.0090198,400
$0.0080-0.0020-20.0%$0.0090$0.0110$0.00801,439,300
$0.01000.00000.0%$0.0100$0.0120$0.0100475,900
$0.0100-0.0010-9.1%$0.0120$0.0120$0.010083,900
$0.01100.00000.0%$0.0100$0.0120$0.0100145,800

Splits

2 splits since 2025 · OTC:CERO · every price before a split is adjusted for it

DayRatioWhat
1-for-20Consolidation
1-for-100Consolidation
Ticker
OTC:CERO
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
OTC
Currency
USD

What changed lately

Latest news

All CERo Therapeutics Holdings, Inc. news

CERo Therapeutics Holdings, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
6 in the last 12 months · 6 in all · newest Nov 20, 2026 · oldest 2026
Decks
7 decks · latest Jan 7, 2026

Valuation

Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$190,890 USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
Negative equity
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
Negative equity
Beta vs S&P 500
1.47

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
CERo Therapeutics Holdings, Inc. · OTC:CEROUS$265,035−US$190,890n/an/an/an/an/an/a1.47
Mushrooms, Inc. · OTC:MSRMUS$539,339US$564,177n/an/an/an/an/an/a1.24
Jaguar Health, Inc. · NASDAQ:JAGXUS$527,406−US$1.48Mn/a−0.1×n/a0.0×−181.8%0.2×3.75
Altamira Therapeutics Ltd. · OTC:CYTOFUS$404,655US$400,900n/an/an/a0.1×n/a0.0×0.64
NKGen Biotech Inc. · OTC:NKGNUS$391,807US$38.58Mn/an/an/an/an/an/a0.88
Vaxil Bio Ltd. · TSXV:VXLUS$319,500−US$4,0701.2×n/an/a0.4×n/a0.0×-0.16
Chimeric Therapeutics Limited · ASX:CHMUS$292,816−US$220,193n/a−0.1×n/a0.2×−262.8%2.5×n/a
CDT Equity Inc. · NASDAQ:CDTUS$234,109−US$1.49Mn/an/an/a0.0×n/a0.0×1.14
GlucoTrack, Inc. · NASDAQ:GCTKUS$217,049−US$887,951n/an/an/an/an/an/a1.73
Regen BioPharma, Inc. · OTC:RGBPUS$167,528US$167,289n/a0.7×n/an/a−501.4%n/a1.20
CNBX Pharmaceuticals Inc. · OTC:CNBXUS$160,577US$151,090n/an/an/an/an/an/a1.78
Median of the othersUS$306,158US$73,5101.2×−0.1×0.1×−262.8%0.0×1.20

Forecasts

1 buy · 1 hold · Analysts' consensus from EODHD, read Nov 11, 2026. Not 6ix's view and not investment advice.

Price target
30.00 USD · Analysts' mean
EPS, year to Dec 2026
-2.50 · 1 analyst

Team and board

Officers

OfficerRole
Chris EhrlichChief Executive Officer & Chair
Andrew Albert Al KucharchukChief Financial Officer & Director
Kristen PierceChief Development Officer & Director

Board

DirectorRole
Chris EhrlichChief Executive Officer & Chair
Andrew Albert Al KucharchukChief Financial Officer & Director
Brandon CieniewiczDirector
Brian AtwoodDirector
Eric FrancoisDirector
Kathleen LaPorteDirector
Kristen PierceChief Development Officer & Director
Lindsey RolfeDirector
Michael ByrnesDirector
Shami PatelDirector

Events

QuarterResultsShare move
Q3 2025Nov 19, 2025 · After close+16.7%
Q2 2025Aug 22, 2025 · After close−5.3%
Q1 2025May 15, 2025 · After close+0.2%
Quarter to Dec 31, 2024Feb 26, 2025+3.2%
Q4 2022Mar 24, 20230.0%
Q3 2022Nov 10, 2022+0.1%
Q2 2022Aug 11, 20220.0%
Q1 2022May 13, 2022+0.0%
Quarter to Dec 31, 2021Mar 24, 2022+0.1%
Q3 2021Nov 19, 2021

Open Events

Decks

DeckKindSlidesDate
Corporate Update (January 2026)Corporate update15 slidesJan 7, 2026
Investor Presentation (September 2025)Investor deck22 slidesSep 22, 2025
Investor Presentation (April 2025)Investor deck23 slidesApr 25, 2025
Phoenix Biotech Acquisition — SPAC Merger (August 2023)SPAC merger46 slidesAug 14, 2023
Phoenix Biotech Acquisition — SPAC Merger (June 2023)SPAC merger45 slidesJun 5, 2023
SPAC Merger (June 2023)SPAC merger45 slidesJun 5, 2023
Phoenix Biotech Acquisition — SPAC Merger (October 2022)SPAC merger32 slidesOct 31, 2022

Open Decks

IPO

Went public as PHOENIX BIOTECH ACQUISITION CORP., a blank check company (SPAC). Priced at US$10.00 a unit on Oct 5, 2021.

Price
US$10.00 a unit
Units offered
15,500,000 units
Offering size
US$155 million
Underwriters' option
Up to 2,325,000 more units
Underwriter
Cantor
Units delivered
On or about Oct 8, 2021

Steps

StepWhen
Draft sent to the SEC in confidenceJul 8, 2021
Filed publiclySep 13, 2021
Amended twiceNewest Sep 28, 2021
Shares registered with an exchangeOct 5, 2021
Declared effective by the SECOct 5, 2021
Final prospectus, with the priceOct 8, 2021

Open IPO · From the cover of the final prospectus (424B4) filed Oct 8, 2021

Financials

Annual, in USD

Income statement

LineFY2025FY2023FY2022
Research and development5.29M
Operating income-7.68M-2.91M
Interest expense-138.3K
Income before tax-19.9M-2.44M-68.6K
Income tax94.8K599.2K
Net income-19.9M-7.29M-667.7K
Earnings per share, basic-0.24-1,248.64-0.05
Earnings per share, diluted-1,248.64

Balance sheet

LineFY2025FY2023FY2022
Cash and equivalents1.70M96.9K475.9K
Current assets2.73M1.97M42.4M
Property, plant and equipment246.1K966.7K
Total assets3.64M5.13M42.4M
Accounts payable7.58M1.67M
Current liabilities9.09M3.51M30.7M
Total liabilities9.09M5.08M39.9M
Shareholders' equity-5.45M-42.1M-11.0M
Shares outstanding83.3M5.84K14.7M

Cash flow

LineFY2025FY2023FY2022
Cash from operations-16.1M-1.52M-1.09M
Cash from investing-7.94M180.8M
Cash from financing-32.6M-138.7M
Dividends paid-127.1K
Share buybacks-33.5M-139.4M
Change in cash-42.0M41.0M

Open Financials

Filings

FilingDateTypeFiled with
10-Q · Quarterly reportNov 13, 2026Quarterly reportSEC
8-K · Current reportOct 7, 2026Material contractSEC
8-K · Current reportAug 31, 2026Material contractSEC
424B3 · ProspectusAug 14, 2026Offer documentSEC
10-Q · Quarterly reportAug 14, 2026Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
424B3 · ProspectusJul 17, 2026Offer documentSEC
8-K · Current reportJul 17, 2026Material contractSEC
25-NSEJul 13, 2026Other filingsSEC
424B3 · ProspectusJun 26, 2026Offer documentSEC
Show 200 filings
FilingDateTypeFiled with
8-K · Current reportJun 26, 2026Material contractSEC
424B3 · ProspectusMay 29, 2026Offer documentSEC
8-K · Current reportMay 29, 2026Material contractSEC
424B3 · ProspectusMay 15, 2026Offer documentSEC
10-Q · Quarterly reportMay 15, 2026Quarterly reportSEC
424B3 · ProspectusMay 1, 2026Offer documentSEC
8-K · Current reportMay 1, 2026Material contractSEC
424B3 · ProspectusMay 1, 2026Offer documentSEC
10-K/A · Annual report, amendedApr 30, 2026Annual reportSEC
4 · Change in ownershipApr 21, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 21, 2026Insider tradeSEC
424B3 · ProspectusApr 15, 2026Offer documentSEC
10-K · Annual reportApr 15, 2026Annual reportSEC
424B3 · ProspectusApr 14, 2026Offer documentSEC
8-K · Current reportApr 14, 2026Material contractSEC
NT 10-K · Late filing noticeApr 1, 2026Explanation requestSEC
SCHEDULE 13G · Big-stake noticeMar 12, 2026Big-stake noticeSEC
424B3 · ProspectusMar 10, 2026Offer documentSEC
8-K · Current reportMar 10, 2026Material contractSEC
424B3 · ProspectusFeb 20, 2026Offer documentSEC
8-K · Current reportFeb 13, 2026Material contractSEC
424B3 · ProspectusFeb 4, 2026Offer documentSEC
8-K · Current reportFeb 4, 2026Current reportSEC
424B3 · ProspectusFeb 3, 2026Offer documentSEC
8-K · Current reportFeb 3, 2026Current reportSEC
4 · Change in ownershipJan 9, 2026Insider tradeSEC
4 · Change in ownershipJan 9, 2026Insider tradeSEC
4 · Change in ownershipJan 9, 2026Insider tradeSEC
4 · Change in ownershipJan 9, 2026Insider tradeSEC
4 · Change in ownershipJan 9, 2026Insider tradeSEC
4 · Change in ownershipJan 9, 2026Insider tradeSEC
4 · Change in ownershipJan 9, 2026Insider tradeSEC
4 · Change in ownershipJan 9, 2026Insider tradeSEC
424B3 · ProspectusJan 8, 2026Offer documentSEC
8-K · Current reportJan 7, 2026Current reportSEC
424B3 · ProspectusDec 19, 2025Offer documentSEC
8-K · Current reportDec 19, 2025Management or board changeSEC
EFFECT · Notice that a registration is effectiveDec 12, 2025Other filingsSEC
CORRESP · Letter to the SECDec 9, 2025Other filingsSEC
S-1 · Registration statementDec 5, 2025Offer documentSEC
424B3 · ProspectusDec 2, 2025Offer documentSEC
424B3 · ProspectusDec 2, 2025Offer documentSEC
DEFA14A · Additional proxy materialDec 2, 2025Meeting noticeSEC
8-K · Current reportDec 2, 2025Material contractSEC
DEF 14A · Proxy statementNov 28, 2025Meeting noticeSEC
424B3 · ProspectusNov 20, 2025Offer documentSEC
424B3 · ProspectusNov 20, 2025Offer documentSEC
10-Q · Quarterly reportNov 19, 2025Quarterly reportSEC
NT 10-Q · Late filing noticeNov 17, 2025Explanation requestSEC
PRE 14A · Preliminary proxy statementNov 14, 2025Meeting noticeSEC
424B3 · ProspectusOct 30, 2025Offer documentSEC
424B3 · ProspectusOct 30, 2025Offer documentSEC
8-K · Current reportOct 29, 2025Current reportSEC
424B3 · ProspectusOct 23, 2025Offer documentSEC
424B3 · ProspectusOct 23, 2025Offer documentSEC
8-K · Current reportOct 16, 2025Material contractSEC
8-K · Current reportOct 14, 2025Material contractSEC
8-K · Current reportSep 22, 2025Current reportSEC
424B3 · ProspectusSep 5, 2025Offer documentSEC
424B3 · ProspectusSep 5, 2025Offer documentSEC
8-K · Current reportSep 5, 2025Current reportSEC
424B3 · ProspectusSep 4, 2025Offer documentSEC
424B3 · ProspectusSep 4, 2025Offer documentSEC
8-K · Current reportSep 4, 2025Current reportSEC
424B3 · ProspectusAug 22, 2025Offer documentSEC
424B3 · ProspectusAug 22, 2025Offer documentSEC
10-Q · Quarterly reportAug 22, 2025Quarterly reportSEC
EFFECT · Notice that a registration is effectiveAug 18, 2025Other filingsSEC
NT 10-Q · Late filing noticeAug 15, 2025Explanation requestSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
CORRESP · Letter to the SECAug 14, 2025Other filingsSEC
UPLOAD · Letter from the SECAug 14, 2025Other filingsSEC
S-3 · Registration statementAug 8, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveJul 30, 2025Other filingsSEC
S-8 · Registration statement for employee plansJul 28, 2025Offer documentSEC
CORRESP · Letter to the SECJul 28, 2025Other filingsSEC
424B3 · ProspectusJul 25, 2025Offer documentSEC
UPLOAD · Letter from the SECJul 25, 2025Other filingsSEC
S-1 · Registration statementJul 21, 2025Offer documentSEC
8-K · Current reportJul 18, 2025FinancingSEC
424B3 · ProspectusJul 14, 2025Offer documentSEC
8-K · Current reportJul 14, 2025Material contractSEC
8-K · Current reportJul 8, 2025Current reportSEC
424B3 · ProspectusJul 2, 2025Offer documentSEC
8-K · Current reportJun 30, 2025Material contractSEC
424B3 · ProspectusJun 25, 2025Offer documentSEC
8-K · Current reportJun 17, 2025Current reportSEC
424B3 · ProspectusJun 16, 2025Offer documentSEC
8-K · Current reportJun 13, 2025Current reportSEC
8-K · Current reportJun 11, 2025Current reportSEC
424B3 · ProspectusJun 6, 2025Offer documentSEC
8-K · Current reportJun 6, 2025FinancingSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
8-K · Current reportJun 2, 2025Management or board changeSEC
EFFECT · Notice that a registration is effectiveMay 30, 2025Other filingsSEC
8-K · Current reportMay 29, 2025Management or board changeSEC
POS AM · Amendment to an effective registrationMay 23, 2025Offer documentSEC
10-Q · Quarterly reportMay 15, 2025Quarterly reportSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2025Big-stake noticeSEC
8-K · Current reportMay 8, 2025Current reportSEC
3/A · Initial statement of ownership, amendedMay 8, 2025Insider tradeSEC
UPLOAD · Letter from the SECMay 7, 2025Other filingsSEC
ARS · Annual report to shareholdersMay 6, 2025Annual reportSEC
DEF 14A · Proxy statementMay 6, 2025Meeting noticeSEC
DMay 6, 2025Other filingsSEC
CORRESP · Letter to the SECMay 2, 2025Other filingsSEC
PRER14AMay 2, 2025Other filingsSEC
UPLOAD · Letter from the SECMay 1, 2025Other filingsSEC
10-K/A · Annual report, amendedApr 28, 2025Annual reportSEC
PRE 14A · Preliminary proxy statementApr 25, 2025Meeting noticeSEC
8-K · Current reportApr 25, 2025Current reportSEC
8-K · Current reportApr 22, 2025Material contractSEC
10-K · Annual reportApr 15, 2025Annual reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedApr 4, 2025Big-stake noticeSEC
4 · Change in ownershipApr 4, 2025Insider tradeSEC
NT 10-K · Late filing noticeApr 1, 2025Explanation requestSEC
4 · Change in ownershipMar 6, 2025Insider tradeSEC
4 · Change in ownershipMar 6, 2025Insider tradeSEC
4 · Change in ownershipMar 6, 2025Insider tradeSEC
4 · Change in ownershipMar 6, 2025Insider tradeSEC
4 · Change in ownershipMar 6, 2025Insider tradeSEC
4 · Change in ownershipMar 6, 2025Insider tradeSEC
4 · Change in ownershipFeb 26, 2025Insider tradeSEC
4 · Change in ownershipFeb 26, 2025Insider tradeSEC
4 · Change in ownershipFeb 26, 2025Insider tradeSEC
4 · Change in ownershipFeb 26, 2025Insider tradeSEC
4 · Change in ownershipFeb 26, 2025Insider tradeSEC
4 · Change in ownershipFeb 26, 2025Insider tradeSEC
424B3 · ProspectusFeb 13, 2025Offer documentSEC
424B3 · ProspectusFeb 13, 2025Offer documentSEC
424B3 · ProspectusFeb 13, 2025Offer documentSEC
424B3 · ProspectusFeb 13, 2025Offer documentSEC
8-K · Current reportFeb 12, 2025Current reportSEC
4 · Change in ownershipFeb 7, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedFeb 7, 2025Big-stake noticeSEC
424B3 · ProspectusFeb 7, 2025Offer documentSEC
8-K · Current reportFeb 6, 2025Material contractSEC
EFFECT · Notice that a registration is effectiveFeb 6, 2025Other filingsSEC
CORRESP · Letter to the SECFeb 5, 2025Other filingsSEC
S-1/A · Registration statement, amendedFeb 5, 2025Offer documentSEC
CORRESP · Letter to the SECFeb 3, 2025Other filingsSEC
CORRESP · Letter to the SECJan 31, 2025Other filingsSEC
CORRESP · Letter to the SECJan 28, 2025Other filingsSEC
CORRESP · Letter to the SECJan 27, 2025Other filingsSEC
UPLOAD · Letter from the SECJan 23, 2025Other filingsSEC
424B3 · ProspectusJan 23, 2025Offer documentSEC
424B3 · ProspectusJan 23, 2025Offer documentSEC
424B3 · ProspectusJan 23, 2025Offer documentSEC
424B3 · ProspectusJan 23, 2025Offer documentSEC
8-K · Current reportJan 21, 2025Current reportSEC
S-1/A · Registration statement, amendedJan 21, 2025Offer documentSEC
424B3 · ProspectusJan 14, 2025Offer documentSEC
424B3 · ProspectusJan 14, 2025Offer documentSEC
424B3 · ProspectusJan 14, 2025Offer documentSEC
424B3 · ProspectusJan 14, 2025Offer documentSEC
8-K · Current reportJan 10, 2025FinancingSEC
424B3 · ProspectusJan 7, 2025Offer documentSEC
424B3 · ProspectusJan 7, 2025Offer documentSEC
424B3 · ProspectusJan 7, 2025Offer documentSEC
424B3 · ProspectusJan 7, 2025Offer documentSEC
8-K · Current reportJan 7, 2025Current reportSEC
8-K · Current reportJan 6, 2025Current reportSEC
424B3 · ProspectusJan 3, 2025Offer documentSEC
424B3 · ProspectusJan 3, 2025Offer documentSEC
424B3 · ProspectusJan 3, 2025Offer documentSEC
8-K · Current reportDec 31, 2024FinancingSEC
UPLOAD · Letter from the SECDec 26, 2024Other filingsSEC
S-1 · Registration statementDec 23, 2024Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedDec 17, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeDec 13, 2024Big-stake noticeSEC
4 · Change in ownershipDec 13, 2024Insider tradeSEC
4 · Change in ownershipDec 10, 2024Insider tradeSEC
S-8 · Registration statement for employee plansDec 9, 2024Offer documentSEC
8-K · Current reportDec 6, 2024Management or board changeSEC
EFFECT · Notice that a registration is effectiveDec 6, 2024Other filingsSEC
EFFECT · Notice that a registration is effectiveDec 6, 2024Other filingsSEC
424B3 · ProspectusDec 5, 2024Offer documentSEC
424B3 · ProspectusDec 5, 2024Offer documentSEC
4 · Change in ownershipDec 4, 2024Insider tradeSEC
4 · Change in ownershipDec 4, 2024Insider tradeSEC
4 · Change in ownershipDec 4, 2024Insider tradeSEC
4 · Change in ownershipDec 4, 2024Insider tradeSEC
4 · Change in ownershipDec 4, 2024Insider tradeSEC

This page holds 200 of 446 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from CERo Therapeutics Holdings, Inc.’s releases

Common shares
71,630,992
Fully diluted
71,630,992

Fully diluted

LineShares
Common shares71,630,992

Share count over time

CountShares
Nov 22, 202671,630,992

Open Cap table

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Andrew Kucharchuk
Other companies: RRE Ventures Acquisition Corp. (Chief Financial Officer · Since at least Apr 29, 2026); Range Capital Acquisition Corp II (Chief Financial Officer · Since at least Oct 2, 2025); Windtree Therapeutics, Inc. (Director · Since at least Aug 3, 2025); Chain Bridge I (Chief Financial Officer · Apr 1, 2024 – Apr 1, 2024 · Past); Adhera Therapeutics Inc. (Chief Executive Officer, Director · Jul 7, 2020 – Jul 7, 2020 · Past); OncBioMune Pharmaceuticals Inc (Director · May 9, 2018 – Jun 5, 2020 · Past)
Chief Financial Officer & Director · Since at least Oct 1, 2024
Caroline M Loewy
Other companies: eFFECTOR Therapeutics Inc (Director · Sep 9, 2023 – Jun 13, 2024 · Past); Zogenix Inc (Director · Sep 21, 2020 – Mar 7, 2022 · Past); Aptose Biosciences Inc (Director · Dec 21, 2018 – Jan 18, 2022 · Past); PhaseBio Pharmaceuticals Inc (Director · Oct 17, 2018 – May 19, 2023 · Past)
Director · Oct 5, 2021 – Feb 14, 2024 · Past
Barbara Kosacz
Other companies: XOMA Royalty Corporation (Director · Since at least May 21, 2025); LeonaBio, Inc. (Board Member · Since at least Mar 4, 2021); Kronos Bio Inc (COO & General Counsel · Oct 8, 2020 – Jan 4, 2024 · Past)
Director · Oct 5, 2021 – Feb 14, 2024 · Past
Douglas Carl Fisher
Other companies: Sera Prognostics, Inc. (Chief Business Officer · Jul 14, 2021 – Jan 10, 2022 · Past); Precipio, Inc. (Director · Sep 26, 2017 – Oct 27, 2023 · Past); Vyome Holdings, Inc. (Director · Oct 5, 2016 – Sep 16, 2020 · Past)
President · Oct 5, 2021 – Feb 14, 2024 · Past
Charles Carter
Other companies: Ovid Therapeutics Inc. (Chief Financial Officer · Since at least Jul 6, 2026)
Chief Financial Officer · Feb 14, 2024 – Jun 28, 2024 · Past
Brandon CieniewiczDirector · Since at least Nov 5, 2026
Brian AtwoodDirector · Since at least Oct 7, 2026
Chris EhrlichChief Executive Officer & Chair · Since at least Nov 3, 2026
Daniel CoreyChief Technical Officer, Director · Feb 14, 2024 – Mar 25, 2024 · Past
Eric FrancoisDirector · Since at least Nov 5, 2026
All 16 people
PersonSeat
Kathleen LaPorteDirector · Since at least Nov 5, 2026
Kristen PierceChief Development Officer & Director · Since at least Oct 1, 2024
Lindsey RolfeDirector · Since at least Nov 5, 2026
Michael ByrnesDirector · Since at least Nov 5, 2026
Robyn RapaportDirector · Feb 14, 2024 – Mar 25, 2024 · Past
Shami PatelDirector · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about CERo Therapeutics Holdings, Inc.